We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SNN Boosts Shoulder Repair Portfolio With Integrity Orthopaedics Deal
Read MoreHide Full Article
Key Takeaways
SNN acquires Integrity Orthopaedics to add the Tendon Seam rotator cuff repair system.
SNN to pay $225M upfront plus milestones; deal funded with cash and expected to be margin accretive by 2028.
Integrity's Tendon Seam complements REGENETEN, Q-FIX and AETOS, broadening its shoulder portfolio.
Smith + Nephew (SNN - Free Report) recently strengthened its Sports Medicine portfolio with the acquisition of Integrity Orthopaedics, a US-based developer of the Tendon Seam rotator cuff repair system. The deal adds a differentiated, next-generation repair technology aimed at reducing re-tear rates in a large and growing shoulder repair market, while reinforcing SNN’s strategy of investing in high-impact innovation.
From an investor’s perspective, the acquisition deepens SNN’s leadership in shoulder repair by complementing its existing biological and mechanical solutions.
Likely Trend of SNN Stock Following the News
Following the announcement, the company's shares traded flat in Friday’s trading session. In the last six-month period, shares have gained 8% against the industry’s 7.1% decline. The S&P 500 has risen 12.9% over the same period.
In the long run, the Integrity Orthopaedics acquisition is likely to strengthen SNN by expanding its share in the fast-growing rotator cuff repair (RCR) market and reinforcing its position as a full-spectrum shoulder solutions provider. Over time, this can drive recurring revenue, improve mix toward higher-margin sports medicine products and enhance cross-selling opportunities, supporting sustainable growth and margin expansion.
SNN currently has a market capitalization of $ 13.89 billion.
Image Source: Zacks Investment Research
More on the Acquisition News
Under the agreement, SNN is likely to acquire Integrity Orthopaedics for an upfront cash payment of $225 million, with an additional $225 million tied to performance-based milestones over the next five years. Management expects the transaction to be accretive to group trading profit margins by 2028, suggesting confidence in both commercial execution and operating leverage. Importantly for investors, the deal will be funded through existing cash facilities, keeping leverage below the company’s target of 2x EBITDA, preserving balance sheet flexibility.
The strategic appeal of the acquisition is closely tied to the size and dynamics of the RCR market. Around 500,000 RCR procedures are performed annually in the United States, representing an estimated $875 million market opportunity, yet traditional techniques continue to suffer from 20%–40% structural failure rates.
Integrity Orthopaedics’ Tendon Seam system is designed to address this gap through patented micro-anchors, continuous suturing, individually locked stitches and an integrated delivery instrument. Early clinical experience points to lower re-tear rates, shorter sling times and reduced procedure durations, factors that could meaningfully improve surgeon adoption and patient outcomes.
From a portfolio standpoint, Tendon Seam neatly complements SNN’s existing shoulder ecosystem rather than competing with it. SNN already has strong traction with REGENETEN, used in more than 200,000 procedures, the Q-FIX all-suture anchor platform, and the recently launched AETOS Shoulder System for arthroplasty. Together, these offerings span biological augmentation, mechanical repair, and joint replacement, giving SNN one of the broadest shoulder portfolios in the industry.
With the transaction expected to close before January 2026-end, investors may increasingly view this deal as a long-term growth enabler rather than a near-term financial stretch.Top of Form
Favorable Industry Prospect for SNN
Per a report by Zion Market Research, the global orthopedic trauma devices market size was worth around $18.5 billion in 2022 and is predicted to grow to around $38.2 billion by 2030 at a CAGR of roughly 9.5% between 2023 and 2030.
This surge is caused by the increasing prevalence of road accidents and an aging population worldwide, which together are boosting demand for advanced trauma care solutions.
A Recent Development by SNN
In December 2025, SNN announced its RISE strategy, building on the success of the 12-Point Plan. The strategy targets faster revenue growth, higher profitability, stronger free cash flow and improved ROIC by 2028. Management also raised 2025 guidance, now expecting trading profit margins of at least 19.5% and free cash flow of around $800 million. In addition, SNN outlined further portfolio rationalization, including a $200 million non-cash inventory provision, to simplify operations, reduce capital needs and support performance into 2026 and beyond.Bottom of Form
Estimates for IDEXX’s 2025 earnings per share (EPS) have remained constant at $12.93 in the past 30 days. Shares of the company have risen 12.6% in the past year compared with the industry’s 11.1% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.1%. In the last reported quarter, it delivered an earnings surprise of 8.3%.
Boston Scientific shares have gained 2.9% in the past year. Estimates for the company’s 2025 EPS have remained constant at $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
STERIS shares have risen 9.1% in the past year. Estimates for the company’s 2025 EPS have increased by 2 cents to $10.23 in the past 30 days. STE’s earnings topped estimates in three of the trailing four quarters and matched on one occasion, delivering an average surprise of 2.6%. In the last reported quarter, it posted an earnings surprise of 2.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
SNN Boosts Shoulder Repair Portfolio With Integrity Orthopaedics Deal
Key Takeaways
Smith + Nephew (SNN - Free Report) recently strengthened its Sports Medicine portfolio with the acquisition of Integrity Orthopaedics, a US-based developer of the Tendon Seam rotator cuff repair system. The deal adds a differentiated, next-generation repair technology aimed at reducing re-tear rates in a large and growing shoulder repair market, while reinforcing SNN’s strategy of investing in high-impact innovation.
From an investor’s perspective, the acquisition deepens SNN’s leadership in shoulder repair by complementing its existing biological and mechanical solutions.
Likely Trend of SNN Stock Following the News
Following the announcement, the company's shares traded flat in Friday’s trading session. In the last six-month period, shares have gained 8% against the industry’s 7.1% decline. The S&P 500 has risen 12.9% over the same period.
In the long run, the Integrity Orthopaedics acquisition is likely to strengthen SNN by expanding its share in the fast-growing rotator cuff repair (RCR) market and reinforcing its position as a full-spectrum shoulder solutions provider. Over time, this can drive recurring revenue, improve mix toward higher-margin sports medicine products and enhance cross-selling opportunities, supporting sustainable growth and margin expansion.
SNN currently has a market capitalization of $ 13.89 billion.
Image Source: Zacks Investment Research
More on the Acquisition News
Under the agreement, SNN is likely to acquire Integrity Orthopaedics for an upfront cash payment of $225 million, with an additional $225 million tied to performance-based milestones over the next five years. Management expects the transaction to be accretive to group trading profit margins by 2028, suggesting confidence in both commercial execution and operating leverage. Importantly for investors, the deal will be funded through existing cash facilities, keeping leverage below the company’s target of 2x EBITDA, preserving balance sheet flexibility.
The strategic appeal of the acquisition is closely tied to the size and dynamics of the RCR market. Around 500,000 RCR procedures are performed annually in the United States, representing an estimated $875 million market opportunity, yet traditional techniques continue to suffer from 20%–40% structural failure rates.
Integrity Orthopaedics’ Tendon Seam system is designed to address this gap through patented micro-anchors, continuous suturing, individually locked stitches and an integrated delivery instrument. Early clinical experience points to lower re-tear rates, shorter sling times and reduced procedure durations, factors that could meaningfully improve surgeon adoption and patient outcomes.
From a portfolio standpoint, Tendon Seam neatly complements SNN’s existing shoulder ecosystem rather than competing with it. SNN already has strong traction with REGENETEN, used in more than 200,000 procedures, the Q-FIX all-suture anchor platform, and the recently launched AETOS Shoulder System for arthroplasty. Together, these offerings span biological augmentation, mechanical repair, and joint replacement, giving SNN one of the broadest shoulder portfolios in the industry.
With the transaction expected to close before January 2026-end, investors may increasingly view this deal as a long-term growth enabler rather than a near-term financial stretch.Top of Form
Favorable Industry Prospect for SNN
Per a report by Zion Market Research, the global orthopedic trauma devices market size was worth around $18.5 billion in 2022 and is predicted to grow to around $38.2 billion by 2030 at a CAGR of roughly 9.5% between 2023 and 2030.
This surge is caused by the increasing prevalence of road accidents and an aging population worldwide, which together are boosting demand for advanced trauma care solutions.
A Recent Development by SNN
In December 2025, SNN announced its RISE strategy, building on the success of the 12-Point Plan. The strategy targets faster revenue growth, higher profitability, stronger free cash flow and improved ROIC by 2028. Management also raised 2025 guidance, now expecting trading profit margins of at least 19.5% and free cash flow of around $800 million. In addition, SNN outlined further portfolio rationalization, including a $200 million non-cash inventory provision, to simplify operations, reduce capital needs and support performance into 2026 and beyond.Bottom of Form
SNN’s Zacks Rank & Key Picks
Currently, SNN carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are IDEXX Laboratories (IDXX - Free Report) , Boston Scientific (BSX - Free Report) and STERIS (STE - Free Report) . Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for IDEXX’s 2025 earnings per share (EPS) have remained constant at $12.93 in the past 30 days. Shares of the company have risen 12.6% in the past year compared with the industry’s 11.1% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.1%. In the last reported quarter, it delivered an earnings surprise of 8.3%.
Boston Scientific shares have gained 2.9% in the past year. Estimates for the company’s 2025 EPS have remained constant at $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
STERIS shares have risen 9.1% in the past year. Estimates for the company’s 2025 EPS have increased by 2 cents to $10.23 in the past 30 days. STE’s earnings topped estimates in three of the trailing four quarters and matched on one occasion, delivering an average surprise of 2.6%. In the last reported quarter, it posted an earnings surprise of 2.6%.